The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; National Cancer Institute; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Hans Gelderblom
No Relationships to Disclose
 
Justin F. Gainor
Consulting or Advisory Role - Boehringer Ingelheim; Jounce Therapeutics; Kyowa Hakko Kirin; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Patrick M. Forde
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Celgene; Seagen
 
Marcus Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis
 
Chia-Chi Lin
No Relationships to Disclose
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals
Honoraria - Blend Therapeutics; Novartis; Novartis; Novartis
Consulting or Advisory Role - Blend Therapeutics; Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - Clovis Oncology; Novartis; Novartis; Novartis
 
Maria Ochoa de Olza
No Relationships to Disclose
 
Jan H.M. Schellens
No Relationships to Disclose
 
Jean-Charles Soria
No Relationships to Disclose
 
Matthew H. Taylor
Honoraria - Eisai
Consulting or Advisory Role - Eisai; Onyx
 
Antonio P. Silva
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Zhonggai Li
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sanela Bilic
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Scott Cameron
Employment - Novartis
Leadership - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Patent relating to IAP biology
Travel, Accommodations, Expenses - Novartis
 
Jeffrey R. Infante
Consulting or Advisory Role - Novartis (Inst)
Research Funding - Novartis (Inst)